3 Firms Guide Near-$2B Deal For Alder BioPharmaceuticals
Danish drugmaker Lundbeck on Monday agreed to buy Alder BioPharmaceuticals, which develops treatments for migraines and autoimmune and inflammatory diseases, for as much as $1.95 billion, in a deal driven by...To view the full article, register now.
Already a subscriber? Click here to view full article